Pharmaceutical Technology

JUNE 5, 2023

Pralsetinib is under clinical development by F. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Hoffmann-La Roche and currently in Phase II for Pancreatic Cancer. Buy the report here.

In-Vitro 100

In-Vitro Drugs Clinical Trials Clinical Trials 100

Drug Discovery World

JANUARY 3, 2023

Merck KGaA will be solely responsible for in vitro and in vivo characterisation, other preclinical work, and all clinical development and potential commercialisation activities relating to any resulting product candidates. . Mersana will receive an upfront payment of $30 million.

Antibody 52

Antibody Development Research Drugs 52

Drug Discovery World

MARCH 26, 2024

DDW’s Megan Thomas caught up with Oliver Rausch, Chief Scientific Officer at Storm Therapeutics, following the ESMO Targeted Anticancer Therapies Congress 2024, a global meeting focusing on promising new anticancer targets and agents, focusing on those in early phase clinical development. MT: What’s next for STORM’s research?

RNA 64

RNA In-Vivo In-Vitro DNA 64

Drug Discovery World

APRIL 25, 2023

University of California researchers have dosed the second participant in their clinical trial to identify a potential cure for HIV utilising CAR-T cell therapy. The trial is the first-in-human clinical study investigating the duo CAR-T cell therapy for the treatment of HIV. In 2021 there were an estimated 1.5

Research 52

Research In-Vitro Clinical Trials Clinical Trials 52

Pharmaceutical Technology

JUNE 6, 2023

According to Globaldata, it is involved in 5 clinical trials, which are ongoing. The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. It also develops RNAi candidates for the treatment of retina diseases. Buy the model here. over FY2021.

Hormones 100

Hormones In-Vitro Genotype Bacteria 100

Drug Discovery World

JUNE 6, 2023

In preclinical studies conducted by the company, BEN-34712 was neuroprotective in a patient-derived, disease-relevant in vitro motor neuron/iAstrocyte co-culture model, demonstrating significant efficacy in both sporadic and familial subtypes of ALS.

Drugs 52

Drugs In-Vivo In-Vitro Clinical Development 52

Drug Discovery World

FEBRUARY 22, 2024

Libra Therapeutics is a San Diego-based biotech focused on developing novel disease-modifying therapeutics, which restore the cellular balance that is disrupted in neurodegenerative diseases. This article is sponsored by Collaborative Drug Discovery. Security built in to CDD Vault is critical when working with multiple CROs.

Clinical Trials 52

Clinical Trials Clinical Trials Trials In-Vivo 52

Drug Discovery World

JULY 3, 2023

Key updates The findings presented by Dr Christian Klein, Head of Oncology Programs and Department Head of Cancer Immunotherapy Discovery, Roche Innovation Center Zurich, Roche Pharma Research & Early Development, pRED, bear major implications for the development of the next-generation of IL-2 therapies.

Antibody 52

Antibody In-Vitro Engineer In-Vivo 52

XTalks

MARCH 1, 2021

Pfizer/BioNTech are executing the three-dose study to also determine the effectiveness of a third dose against evolving variants as part of their clinical development strategy. Sera from individuals will also be taken to evaluate neutralization of different SARS-CoV-2 strains in in vitro studies.

Vaccination 111

Vaccination Vaccine Development In-Vitro 111

pharmaphorum

JULY 6, 2022

The JV has been formed German pharma companies Boehringer Ingelheim and Evotec with in vitro diagnostics specialist bioMérieux, with the objective of developing new antimicrobial drugs backed by diagnostics to quickly identify pathogens and their resistance patterns and guide treatment.

In-Vitro 57

In-Vitro Development Pharma Companies Drugs 57

Drug Discovery World

AUGUST 7, 2023

DDW’s Reece Armstrong speaks to Shantanu Dhamija , VP of Strategy and Innovation at Molecular Devices about challenges of diversity in clinical trials and why induced pluripotent stem cells might be key to representing wider patient groups. RA: Why is US clinical trial diversity at its lowest point in the last 10 years?

Development 98

Development Clinical Trials Clinical Trials Drugs 98

pharmaphorum

JANUARY 16, 2023

There were developments in the past 12 months, true – Biogen/Eisai’s lecanemab (now branded Leqembi) showed clear success in the Clarity AD trial and received approval by FDA on 6th January 2023. The hard problem: innovation for high prevalence, chronic diseases of ageing.

Gene Therapy 96

Gene Therapy In-Vitro Gene Medicine 96

Drug Discovery World

FEBRUARY 15, 2023

Further studies elucidating the role of tumour microenvironment and its immunosuppressive elements including tumour associated macrophages have shown encouraging results in improving the efficacy of IO therapies. Over 250 clinical trials are currently in progress, and novel immuno-oncological treatments are already proving to be successful.

Research 52

Research In-Vitro In-Vivo Development 52

pharmaphorum

NOVEMBER 9, 2022

A pre-clinical pipeline of potential first-in-class brain-penetrant small molecule inhibitors of the mitochondrial permeability pore (mPTP) are to be developed. Inhibition of the mPTP has been shown, however, to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models.

In-Vitro 52

In-Vitro Bioavailability Medicine Clinical Trials 52

pharmaphorum

OCTOBER 29, 2020

The platform applies machine learning, human genetics, and functional genomics to generate predictive in vitro models that provide insights into disease progression. The platform applies machine learning, human genetics, and functional genomics to generate predictive in vitro models that provide insights into disease progression.

Development 44

Development DNA In-Vitro Genome 44

XTalks

NOVEMBER 15, 2023

XTALKS WEBINAR: Vaccine Clinical Development: Key Ingredients to Improve Efficiency Live and On-Demand: Monday, November 20, 2023, at 10am EST (4pm CET/EU-Central) Register for this free webinar to learn ways to improve the efficiency of vaccine development. Fever and joint pain are the most common symptoms of chikungunya.

FDA Approval 59

FDA Approval Vaccination Vaccine In-Vitro 59

The Pharma Data

DECEMBER 22, 2020

Merck will assist with preclinical development and has the option to exclusively develop, manufacture and commercialize the candidate following Phase 1. A2 will also receive from Merck an equity investment and reimbursement of certain expenses. Merck has the option to designate a new Tmod program with increased economic terms.

Development 52

Development Engineer Manufacturing In-Vitro 52

Drug Discovery World

FEBRUARY 28, 2023

With only 10% of these conditions indicated for an approved therapy, there is a sizable opportunity for scientists and companies to develop treatments for patients with no other options to turn to. Approximately 7,000 rare and ultra-rare diseases have been described, and yet, 90% have no approved therapeutic options 1.

Genetics 52

Genetics Genetic Analysis Vaccination Vaccine 52

The Pharma Data

JANUARY 6, 2021

SK Chemicals has shared their expertise in these diseases and validated the predicted targets and compounds through in vitro and in vivo studies. Further research on and development of the compound is ongoing with the objective of completing preclinical studies. About Standigm. Standigm is an AI-driven drug discovery company.

FDA Approval 52

FDA Approval Life Science Drugs In-Vivo 52

The Pharma Data

JANUARY 19, 2021

The proceeds will be used to fund its ongoing clinical and preclinical programs. The company is using its pioneering FasTCAR and TruUCAR technology platforms to discover and develop breakthrough cell therapies. Ortho Clinical Diagnostics is a leader in in vitro diagnostics. TCR2 Therapeutics – The Cambridge, Mass.

In-Vitro 52

In-Vitro Production Trials Manufacturing 52

The Pharma Data

JANUARY 12, 2021

Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g. Dr. Graham earned an M.D.,

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

Drug Discovery World

JANUARY 17, 2024

Challenges in the Oncology Clinical Trials Space The oncology market is a key growth driver for the pharma industry, with global drug revenues expected to reach US$390 billion by 2027 and the annual number of new cancer cases set to grow from 18 to 27 million by 2040 1,2.

Medicine 59

Medicine DNA Genome Genomics 59

The Pharma Data

APRIL 4, 2022

Chief Medical Officer and Head of Global Product Development, Roche. About the Actemra®/RoActemra® (tocilizumab) COVID-19 Clinical Trial Programme Roche’s clinical trial programme evaluated the safety and efficacy of Actemra/RoActemra in hospitalised patients with COVID-19. A decision on U.S. Actemra/RoActemra is not U.S.

FDA Approval 52

FDA Approval Clinical Trials Clinical Trials In-Vitro 52

Pharmaceutical Technology

MAY 26, 2023

Doggybone DNA is named for its bone-shaped schematic structure and produced using an in vitro enzymatic process over 50 days, which is more than five times quicker than the 270 days taken for plasmid DNA E.Coli fermentation process. One big pharma company has already given the seal of approval with a successful customer quality audit.

DNA 130

DNA Manufacturing Gene Therapy Gene 130

The Pharma Data

DECEMBER 14, 2020

AbbVie has initiated a Phase I clinical trial of the antibody, and it will conduct the initial clinical program in the U.S. “With the clinical program at AbbVie now underway, we are in a position to contribute a new therapeutic option to address this pandemic.” before expanding it into Europe.

Antibody 52

Antibody Licensing Licensing In-Vitro 52

The Pharma Data

APRIL 22, 2023

UC Davis Health researchers have dosed the second participant in their clinical trial looking to identify a potential cure for HIV utilizing CAR T-cell therapy. The trial is the first-in-human clinical study investigating the duoCAR T-cell therapy for the treatment of HIV. The novel study uses immunotherapy.

Clinical Trials 40

Clinical Trials Clinical Trials Trials In-Vitro 40

The Pharma Data

MAY 31, 2022

More than 5,000 patients have now been treated worldwide with Evrysdi in clinical trials, compassionate use or real-world settings. Roche leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics. Jude Children’s Research Hospital.

FDA Approval 52

FDA Approval Protein In-Vitro Medicine 52

The Pharma Data

APRIL 29, 2022

Among the infants with an available assessment (n=48) treated with Evrysdi, 32 infants maintained and four gained the ability to sit without support for at least five seconds since month 24, as assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler Development Third Edition (BSID-III).

Protein 52

Protein In-Vitro Medicine Development 52

The Pharma Data

MAY 27, 2022

Glofitamab is being investigated in several clinical trials and explored in earlier lines of lymphoma treatment. About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics.

Antibody 52

Antibody In-Vitro Medicine Engineer 52

The Pharma Data

NOVEMBER 12, 2021

COMET-TAIL Phase III data demonstrated that intramuscular administration of sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations The trial enrolled participants during the Delta variant wave of the pandemic in the US. GlaxoSmithKline plc (LSE/ NYSE GSK) and Vir Biotechnology,Inc.

Trials 40

Trials In-Vitro Antibody Clinical Development 40

The Pharma Data

MARCH 29, 2022

Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months Evusheld retains neutralising activity against the Omicron BA.2 2 subvariant, now the dominant strain in Europe. 1-3 Evusheld was generally well-tolerated in the trial. Christoph D.

Antibody 52

Antibody In-Vivo Vaccination Vaccine 52

The Pharma Data

OCTOBER 21, 2020

Company is on t rack to s ubmit an IND in the fourth quarter of 2020 and i nitiate a Phase 1 /2 clinical trial for advanced solid tumors in 2021. We look forward to advancing clinical development of KB-0742 to establish the dose, safety and efficacy of this investigational therapy as a potential treatment for MYC-amplified tumors.”.

In-Vivo 40

In-Vivo In-Vitro Bioavailability Clinical Trials 40

Drug Discovery World

AUGUST 2, 2023

Palmitoyl transferases are a zinc finger Asp-His-His-Cystype (ZDHHC) family containing 23 distinct mammalian genes (excluding ZDHHC10) that catalyse this reaction 1. Conformational changes in the Ras membrane proximal domain facilitate the phosphorylation of GDP to GTP and the kinase domain activation.

Protein 52

Protein Immune Response In-Vitro Regulation 52

The Pharma Data

MAY 15, 2023

Roche’s Chief Medical Officer and Head of Global Product Development. The sBLA is based on results from the phase III BALATON and COMINO studies that demonstrated treatment with Vabysmo provided early and sustained improvement in vision, meeting the primary endpoint of non-inferior visual acuity gains at 24 weeks compared to aflibercept.

Antibody 40

Antibody In-Vitro Clinical Development Medicine 40

The Pharma Data

OCTOBER 22, 2020

The Company intends to use the net proceeds from this offering to support its planned New Drug Application submission for oral sulopenem for the treatment of uncomplicated urinary tract infections in patients with quinolone-resistant pathogens, the continued clinical development of sulopenem, and for working capital and general corporate purposes.

In-Vitro 40

In-Vitro Clinical Trials Clinical Trials Sales 40

Drug Discovery World

MAY 16, 2023

Skills gap Bruce Levine, International Society for Cell & Gene Therapy (ISCT) Immediate Past President and Chair, Strategic Advisory Council, says a critical challenge that has become apparent for the CGT sector is the need for workforce development and training resources. What are the global innovations in cell and gene therapy?

Gene Therapy 52

Gene Therapy Gene Manufacturing Marketing 52

The Pharma Data

MARCH 26, 2021

Preclinical data suggest VIR-7831 targets a highly conserved epitope of the spike protein, which may make it more difficult for resistance to develop. About the VIR-7831 Clinical Development Programme. The interim analysis included 291 patients in the treatment arm and 292 patients in the placebo arm.

Antibody 52

Antibody Trials Vaccination Vaccine 52